Saturday, April 25
11:30 – 13:00
New symptoms managements and treatment of co-morbidities in ILDs
This session will focus on comorbid conditions in patients with fibrotic lung diseases. Current knowledge is that comorbid conditions have a significant impact on symptoms, health related quality of life and outcomes in ILDs. Some evidence speaks for profound investigation for comorbidities and consequent treatment. Distinct entities and their treatments, such as lung cancer however are associated with a significant deterioration of the underlying ILD. These aspects will be discussed in this session.
- Comorbidities and co-medications in fibrotic ILDs, namely pulmonary hypertension, lung cancer, reflux and emphysema.
A keynote speech by Prof. Dr. Kreuter, followed by a keynote speech from a patient and/or patient representative. The session will close with a live Q&A session with the audience.
More coming soon
Please note that the programme is still updated on a regular basis until finalised.